Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference

Ventrus Biosciences to Present at the Leerink Swann Global Healthcare

NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc.
(Nasdaq:VTUS), a pharmaceutical company focused on developing and
commercializing gastrointestinal products, today announced that Dr. Russell
Ellison, Chairman and Chief Executive Officer, will be presenting at the
Leerink Swann Global Healthcare Conference on Thursday, February 14^th at 1:30
p.m. Eastern Time at the Waldorf Astoria Hotel in New York.

A live webcast and replay of the presentation will be available on the
"Investors" section of the Company's website.

About Ventrus Biosciences

Ventrus is a development stage pharmaceutical company focused on the
development of late-stage prescription drugs for gastrointestinal problems,
specifically anal disorders. Our lead product is topical diltiazem (VEN 307)
for the treatment of anal fissures, for which the first Phase 3 trial was
initiated in November 2010, and reported positive top line results in May
2012. The second Phase 3 trial began enrollment in the fourth quarter of 2012
and is ongoing. Our product candidate portfolio also includes topical
phenylephrine (VEN 308) intended to treat fecal incontinence. VEN 307 and VEN
308 are two molecules that were previously approved and marketed for other
indications and that have been formulated into our in-licensed proprietary
topical treatments for these new gastrointestinal indications.

Please Note: The information provided herein contains estimates and other
forward-looking statements regarding future events. Such statements are just
predictions and are subject to risks and uncertainties that could cause the
actual events or results to differ materially. These risks and uncertainties
include, among others: our ability to complete the offerings, including the
satisfaction of the closing conditions for each offering; the estimated
proceeds from each offering and our use of the anticipated proceeds from the
offerings; the components, timing, cost and results of clinical trials and
other development activities involving our product candidates; the
unpredictability of the clinical development of our product candidates and of
the duration and results of regulatory review of those candidates by the FDA
and foreign regulatory authorities; the unpredictability of the size of the
markets for, and market acceptance of, any of our products; our anticipated
capital expenditures, our estimates regarding our capital requirements, and
our need for future capital; our reliance on our lead product candidate, VEN
307; our ability to retain and hire necessary employees and to staff our
operations appropriately; and the possible impairment of, or inability to
obtain, intellectual property rights and the costs of obtaining such rights
from third parties. The reader is referred to the documents that we file from
time to time with the Securities and Exchange Commission.

CONTACT: Ventrus Biosciences, Inc.
         David Barrett
         Argot Partners
         David Pitts
Press spacebar to pause and continue. Press esc to stop.